Jun 1, 2025, 13:44

Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)

This R01 funding opportunity from the National Cancer Institute (NCI) supports projects that develop or apply in vivo molecular imaging tools to study how inflammation influences tumor behavior. Multidisciplinary teams—led by co-Principal Investigators in cancer biology and imaging science—will integrate cutting-edge probes, quantitative imaging modalities, and complementary assays (e.g., multi-omics or ex vivo imaging) to capture dynamic inflammatory processes in preclinical and/or clinical cancer models.

Eligibility Criteria

Applicant Organizations:
- U.S.-based higher education institutions (public or private)
- Nonprofit organizations (with or without 501(c)(3) status)
- For-profit entities (including small businesses)
- Local, state, and tribal governments
- Federal government agencies
- Independent school districts, public housing authorities, faith-based/community organizations, regional organizations
- Note: Foreign organizations and non-domestic U.S. components are not eligible; foreign components of U.S. institutions are allowed.
PD/PI Requirements:
- Must designate at least two co-PIs—one with expertise in cancer inflammation biology (e.g., immunology, tumor microenvironment) and one in imaging science (e.g., probe development, quantitative molecular imaging). Applications with only a single PI will be considered nonresponsive.
Application Types Allowed: New and Resubmission only.
Clinical Trials: Not allowed.
Budget and Project Period Constraints: Must adhere to R01 guidelines (see “Funding Details” below).

Funding Details

Mechanism: R01 Research Project Grant (independent investigator–initiated).
Budget Limits: Up to $499,999 direct costs per year (budgets should reflect actual project needs).
Project Period: Up to 5 years.
Anticipated Number of Awards: Dependent on NCI appropriations and the number of meritorious applications.
NIH Policy Compliance: Applicants must follow all SF424(R&R) application instructions, NIH Genomic Data Sharing, and NIH Data Management and Sharing policies.

Deadline

First Available Due Date (New & Resubmission): February 5, 2025, by 5:00 PM local time
Subsequent Standard Due Dates:
- June 5, 2025
- October 5, 2025
- February 5, 2026
- June 5, 2026
- October 5, 2026
- February 5, 2027
- June 5, 2027
- October 5, 2027
Letters of Intent (Optional): Due 30 days before each application deadline.
Expiration Date: January 8, 2028
All applications must be submitted via Grants.gov and tracked in eRA Commons. Late submissions will not be accepted.

Where to Go for Further Information

Full Announcement: Search FOA number PAR-24-311 on Grants.gov or visit the NIH Guide for Grants and Contracts.
Scientific/Technical Questions:
- Charles Lin, Ph.D.
  
  Division of Cancer Diagnosis and Treatment, NCI
  
  Email: [email protected]
Peer Review Contact:
- Referral Officer, NCI
  
  Tel: 240-276-6390
  
  Email: [email protected]
Grants Management Contact:
- Shane Woodward
  
  National Cancer Institute
  
  Tel: 240-276-6303
  
  Email: [email protected]